Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

PURPOSE: The pharmacokinetics (PK) of carfilzomib have been previously studied in multiple myeloma patients with varying degrees of renal impairment (normal, mild, moderate, severe, and end-stage renal disease [ESRD]) at doses of 15 and 20 mg/m(2). This study evaluated carfilzomib PK at higher doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Quach, Hang, White, Darrell, Spencer, Andrew, Ho, P. Joy, Bhutani, Divaya, White, Mike, Inamdar, Sandeep, Morris, Chris, Ou, Ying, Gyger, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438822/
https://www.ncbi.nlm.nih.gov/pubmed/28424963
http://dx.doi.org/10.1007/s00280-017-3287-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438822/
https://www.ncbi.nlm.nih.gov/pubmed/28424963
http://dx.doi.org/10.1007/s00280-017-3287-8

Ejemplares similares